523 related articles for article (PubMed ID: 29580635)
1. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
Vervloet MG; van Ballegooijen AJ
Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
[TBL] [Abstract][Full Text] [Related]
2. Phosphate management in chronic kidney disease.
Bhan I
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
[TBL] [Abstract][Full Text] [Related]
3. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
4. Oral phosphate binders in CKD - is calcium the (only) answer?
Goldsmith D; Covic A
Clin Nephrol; 2014 Jun; 81(6):389-95. PubMed ID: 25017668
[TBL] [Abstract][Full Text] [Related]
5. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
6. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
7. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
8. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
[TBL] [Abstract][Full Text] [Related]
9. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
10. Educating your patient helps to control serum phosphate and also save 200 euros per patient.
Rodriguez-Palomares JR; Japaz Cancino MC; Blazquez Collado L; Fiallos Criollo R; Villabon Ochoa PM; Sanchez Heras M; Basterrechea MA; de Arriba de la Fuente G
Nefrologia; 2017; 37(1):103-105. PubMed ID: 27825657
[No Abstract] [Full Text] [Related]
11. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
12. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
13. Niacin and Chronic Kidney Disease.
Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota; an overlooked effect of phosphate binders.
Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
[TBL] [Abstract][Full Text] [Related]
16. The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
Elder GJ; Center J
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():42-46. PubMed ID: 28429551
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
18. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
19. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]